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a  b s t  r a c  t
Despite  wide antiretroviral  scale-up during  the past  two decades  resulting  in declining  new  infections  and
mortality  globally,  HIV-associated  tuberculosis remains  as a major public  health concern.  Tuberculosis  is
the  leading  HIV-associated opportunistic  infection and  the  main  cause  of death  globally and, particularly,
in resource-limited  settings.  Several  challenges  exist regarding  diagnosis,  global  implementation  of latent
tuberculosis  treatment,  management  of active tuberculosis, delivery  of optimal patient-centered TB  and
HIV  prevention  and  care  in high  burden countries.  In  this article we review  the  advances  on pathogenesis,
diagnosis, and  treatment  after  nearly two  decades  of  global  roll-out of antiretroviral  therapy and discuss
the  current  challenges for  the  global  control of tuberculosis-HIV  co-infection.
©  2019  The Authors.  Published  by  Elsevier España,  S.L.U. on behalf of SEPAR. This  is an  open access
article under the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Coinfección  tuberculosis-VIH:  avances  y retos  2  décadas  después








Situaciones de recursos limitados
Retos en implementación
r  e  s  u m  e  n
A  pesar  de  que el uso  de  antirretrovirales ha aumentado  en  uso  y difusión  durante las 2 últimas  décadas, lo
que ha resultado  en  la disminución  de  nuevas infecciones  y  de  la mortalidad  global, la tuberculosis asoci-
ada  al VIH  sigue  siendo un  importante  problema  de  salud  pública. La tuberculosis  es la  principal  infección
oportunista  asociada  al VIH  y  la principal  causa de  muerte  a nivel  mundial,  particularmente  en  el  marco
de  situaciones de  recursos limitados. Existen  varios retos  con respecto  al diagnóstico,  la  implementación
global  del  tratamiento  de  la tuberculosis  latente, el  manejo  de  la tuberculosis  activa,  el proporcionar  una
prevención  óptima  de  la tuberculosis y  el VIH centrada  en  el  paciente  y  la  atención  en  países de  alta carga.
En  este  artículo  revisamos  los avances  en la patogénesis,  el  diagnóstico  y  el  tratamiento  después  de  casi
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2 décadas de  implementación  global  de  la terapia  antirretroviral y  comentamos  los retos actuales  para  el
control  global  de  la coinfección  tuberculosis-VIH.
© 2019  Los Autores.  Publicado  por  Elsevier  España, S.L.U.  en  nombre  de  SEPAR.  Este  es un artı́culo  Open
Access  bajo  la licencia  CC BY-NC-ND  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Worldwide, tuberculosis (TB) is the leading cause of death from
a single pathogen. According to the World Health Organization
(WHO), about 10 million developed active tuberculosis disease and
1.6 million people died in  2017.1 Globally, HIV-associated TB  was
estimated to be responsible for about 9% of all new cases and 20%
of all TB-deaths.1 Encouragingly, the prevalence of HIV among new
TB cases is slowly decreasing in recent years. Nevertheless, it is still
unacceptably high in sub-Saharan Africa due to  several challenges.1
Seventy-two per cent of all TB  cases among people living with HIV
(PLHIV) occurred in Africa (Fig. 1). The global burden of disease
study estimates a  slightly lower number of TB cases and less TB-
deaths, especially among PLHIV,2 reflecting under-diagnosis and
under-reporting of TB, a  major obstacle to  estimate the true number
of new cases. Indeed, of the 920,000 HIV-associated TB cases esti-
mated last year by  the WHO, only 51% had been diagnosed and/or
reported. Reducing this diagnostic gap is a priority of the global End
TB strategy.1 PLHIV, including those receiving antiretroviral treat-
ment (ART), have a  30–35 higher risk of developing3 and dying of
TB4 than HIV-negative individuals. It  is therefore paramount that
TB patients starting ART are routinely tested for HIV. Unfortunately,
despite increasing yearly, the proportion of notified TB  cases with
a documented HIV result in 2017 was only of 60%.1
In this article we  review the advances on  pathogenesis, diag-
nosis, treatment, and current challenges for the global control of
TB-HIV co-infection.
Pathogenesis of tuberculosis
Mycobacterium Tuberculosis (MTB) is  transmitted by  droplet
nuclei expelled from the respiratory tract of infected individuals
through coughing and, less frequently, through sneezing, laugh-
ing and singing.5–7 Inhalation and deposition of infected droplet
nuclei in the host lung triggers infection,5,8 where it is recog-
nized and phagocytosed by  alveolar macrophages.6,8,9 Subsequent
course of infection, determined by MTB  virulence and the host
immune response, is mediated by  recruitment and activation of
alveolar macrophages. Inability of alveolar macrophages to destroy
or inhibit MTB  results in intracellular proliferation of the pathogen,
macrophage cell death and pathogen release, which induces a
repeat cycle aimed at limiting further bacterial growth.9,10 MTB
infected alveolar macrophages secrete cytokines and chemokines
that initiate an inflammatory cascade, attracting other phago-
cytic cells to form a granuloma, the hallmark of TB  disease,5,8,10
intended to wall-off the pathogen and limit its spread to  other
organs. Inability of the host immune response to  adequately con-
trol bacterial replication following first infection with MTB  results
in primary TB disease. This either heals with persistence of viable
organisms or progresses to  active TB  disease. Erosion of caseous
necrotic lesions into airways causing mechanical spread of bacilli
results in infectiousness,5 whereas systemic infection results from
migration of TB-infected cells into the lymphatic and circulatory
systems.5,6,10 While focal lesions are typical of TB, lung biopsy stud-
ies demonstrate parenchymal pathology ranging from pulmonary
infiltration with an exudative reaction, granulomatous inflamma-
tion, fibro-caseous disease,5,8 to cavities resulting from necrosis of
tuberculous pneumonia.
Post-primary TB  disease occurs by reactivation of dormant
organisms from previous primary TB  infection, or from exogenous
re-infection. While a  granulomatous process is  seen in  primary
tuberculosis, pathology in post-primary TB follows a  pneumonic
process characterized by accumulation of foamy macrophages in
alveoli of lung apices with acid fast bacilli organisms seen almost
exclusively in  alveolar macrophages. In high bacillary burden dis-
ease, caseous necrosis may  evolve into cavities, which may progress
slowly for up to a  year producing little or no clinical illness.
Active TB disease develops in  approximately 5%  of MTB-infected
individuals within two years. In 90–95%, dormant viable bacte-
ria  survive for years, progressing to active disease at a rate of
10% per lifetime and 10% per annum in HIV-uninfected and PLHIV
respectively.11,12 The innate immune response through B cells and
antibodies mediate MTB  killing directly through stimulation of
antigen presentation, and cytokine production aimed at enhanced
killing of MTB  infected macrophages. Quantitative and qualitative
depletion of CD4 T-cells during HIV infection increases the risk
of MTB disease. Characteristically, this immunologic impairment
is associated with impaired granuloma formation, compromised
MTB containment and increasing bacillary burden.11,13,14 Indeed,
the HIV epidemic has played an important role in increasing the
prevalence of miliary and extrapulmonary TB globally. In turn, TB
enhances HIV viral replication by increasing expression of  viral
growth receptors such as CXCR4.15 Reactivation of latent TB infec-
tion is  likely precipitated by disruption of the stable host-microbe
interaction.15 In PLHIV, multiple factors including diversity in
lung microenvironments, levels of immune activation and cytokine
secretion, and variation in  granuloma genesis, cumulatively expose
MTB  to  varying levels of nutrients and oxygen that promote or pro-
hibit replication, influence TB pathogenesis and disease severity.16
Diagnosis of tuberculosis among people living with HIV
Diagnosis of latent tuberculosis
Two major tests exist for the diagnosis of latent tuberculosis
infection: the tuberculin skin test (TST) and the interferon-gamma
release assays (IGRA).17 A thorough review of these two types of
tests is outside the scope of this article. All newly diagnosed PLHIV
should be screened for latent tuberculosis with TST or IGRA.18,19
Also, those patients tested negative while having low CD4 counts
(<200 cells/L), should be retested after immune reconstitution
above this threshold.18,20 IGRA is generally preferable, if avail-
able, particularly for patients with prior vaccination with Bacille
Calmette-Guérin (BCG) and for patients who are  unlikely to return
to have the TST read. It is reasonable to confirm a  positive TST result
with an IGRA in low TB incidence settings, to rule out nontubercu-
lous mycobacterial infection.21 For those who  test negative with
ongoing risk factors for active TB, annual screening is  warranted.
Testing should not  be repeated among those with a  previously
positive test. Treatment should be  administered to  those with a
positive TST or IGRA results after having excluded active TB. In high
prevalence settings where TST or IGRA are often not available, treat-
ment of latent tuberculosis infection is recommended to all PLHIV
regardless of testing results, after having excluded active TB.22
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Fig. 1. Estimated HIV prevalence in new and relapse TB cases, 2017. Source: Global tuberculosis report 2018, WHO  (1).
Diagnosis of active tuberculosis disease
Diagnosis of active TB  disease in PLHIV is  challenging due to
the differing and non-specific clinical symptoms, and often health-
care workers rely on suggestive radiological changes or  clinical
suspicion.23,24 The level of HIV-associated immunosuppression and
the resulting TB  burden influences the yield of the different avail-
able diagnostic methods, including smear microscopy, culture, PCR,
urine lipoarabinomannan, and whole-genome sequencing (Fig. 2).
Smear microscopy
Historically, diagnosis of TB disease has relied on microscopy
(Ziehl-Neelsen staining of Acid-Fast Bacilli) of fluid or tissue
from TB-affected organs. Although widely available in  laborato-
ries globally, the limited sensitivity of traditional microscopy: ∼50%
sensitive for high bacterial burden TB  disease (such as cavitary PTB
in adults) and 10–20% sensitive in  paucibacillary disease (such as
TB-meningitis), has limited its clinical utility.25
Culture
Culture of clinical specimens for MTB  has a 50–100% sensitiv-
ity depending on bacillary load and the clinical specimen tested.
MTB  culture techniques however: are expensive ($13–$50/unit);
are not universally available; require a  biosafety level-3 laboratory;
and results takes at least 10 days in liquid media (Mycobacteria
Growth Inhibitor Tube culture) and up to  8 weeks on solid media
(Löwenstein-Jensen), too slow to aid clinical decision making.
Commercially available PCR platforms
The introduction of the GeneXpert® MTB/Rif (Xpert) assay
(Cepheid, Sunnyvale, CA, USA) a cartridge-based, real-time PCR
molecular assay in  2010 marked a  new era in TB  diagnostics. Xpert
Fig. 2. Damage response framework in relation to Tuberculosis.
Modified from the damage–response framework of microbial pathogenesis. (24). As
the  immune response is less effective due to  HIV-infection, energy or dysfunctional
responses (e.g. Th2 or neutrophil response) immune control of the pathogen is  less
effective, and TB bacilli are  more easily detected by  microbiologic diagnostics. As
a  more effective Th1immune response occurs, less viable TB bacilli exist and diag-
nosis by  traditional techniques becomes more challenging. In the  extreme, such as
in paradoxical immune reconstitution inflammatory syndrome, immunopathology
can  occur in the absence of viable or detectable organisms. Mortality is highest in
those with the most attenuated or exuberant inflammatory responses.
MTB/RIF has notable benefits over traditional microbiology tech-
niques: Xpert MTB/RIF is fully automated and requires minimal
operator training; a biosafety level-3 laboratory is not required;
and the run-time of ∼2  h enables rapid results turnaround of ∼48 h.
In addition, Xpert MTB/RIF provides preliminary drug sensitivity
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testing (DST) through detection of rpoB gene mutations confer-
ring rifampicin resistance. In a  2014 Cochrane review evaluating
the role of Xpert MTB/RIF in diagnosing PTB, pooled sensitivity
and specificity was 89% (95% CI 85–92%) and 99% (95% CI 98–99%),
respectively.26 In 2011, the WHO  issued a  strong recommendation
for Xpert MTB/RIF to be used as the preferred initial diagnostic test
for sputum samples in  diagnosing PTB27; followed in 2013, by a rec-
ommendation for use with CSF specimens, lymph nodes and other
tissues in diagnosing EPTB.26 However, the suboptimal sensitivity
of Xpert MTB/RIF in  paucibacillary disease and among PLHIV is a  sig-
nificant limitation. Pooled sensitivity from seven studies in PLHIV
was 79% (95% CI 70–86%).26 In 2017, Cepheid therefore introduced
GeneXpert® MTB/Rif Ultra (Ultra) a  re-engineered version of the
Xpert cartridge MTB/RIF platform with technical enhancements,
including larger specimen volume, additional probes for two  other
DNA targets in the mycobacterial genome, optimized fluidics and
PCR cycling and addition of a’trace’ category for the lowest bacil-
lary load. The improved sensitivity of Ultra is purported to have
greatest clinical utility in cohorts of PLHIV. In a multi-center, diag-
nostic accuracy study, comparing Xpert Ultra and Xpert MTB/RIF in
PTB diagnosis, Ultra sensitivity demonstrated a greater additional
diagnostic benefit in PLHIV: 13% difference (95% CI 6.4–21%) com-
pared to 1.3% (95% CI 1.8–4.9%) improvement in  HIV-uninfected
patients.28 A recent study conducted in Uganda showed a  sensi-
tivity of Xpert Ultra of 95% for diagnosing tuberculous meningitis
(TBM), which was higher than Xpert MTB/RIF (45%) and culture
(45%).29 Based on this highly improved sensitivity, the WHO  has
endorsed Ultra,30 including for TBM, and it has been made avail-
able to eligible countries at the same concessional pricing as the
standard Xpert MTB/RIF cartridge.
Urine lipoarabinomannan (LAM) antigen detection
The increasing recognition and availability of urine lipoarabi-
nomannan (LAM) antigen detection lateral flow assays marked
a significant step forward in the diagnosis of disseminated HIV-
associated TB. Urine is  easily obtained without risk of aerosolization
of MTB  and results are  available in  20 min, facilitating timely clin-
ical decision making. The sensitivity of LAM is  only moderate
(pooled sensitivity and specificity across six studies was 44% (95%
31–60%) and 92% (95% 83–96%), respectively31 but its sensitiv-
ity is greatest in those with a CD4 count <100 cells/l. Moreover,
TB-LAM has recently been shown to  have demonstrable clinical
benefit including increased overall TB diagnoses and significant
reduction in mortality in  high risk subgroups: CD4 <100 cells/L;
and hemoglobin <8  g/dl when hospitalized PLHIV underwent sys-
tematic screening.32 TB-LAM LFAs are complementary to other
diagnostics and at ∼$4 per test are potentially a  cost-effective inter-
vention when used in  the appropriate population.
Whole-genome sequencing
Whole genome sequencing of MTB  for detection of drug resis-
tance and typing is increasingly being used in  a  range of clinical and
research settings. The recently demonstrated capacity to sequence
MTB  directly from clinical specimens33 has the potential to revo-
lutionize the TB diagnosis and DST in both high- and low-income
countries.34
Treatment of tuberculosis-HIV co-infection
Treatment of latent tuberculosis
Isoniazid preventive therapy (IPT) has the potential to  deliver
greater health benefits to PLHIV in  high-incidence countries.35 In
the TEMPRANO study, a trial designed to assess the benefits of early
antiretroviral therapy (ART), 6-month IPT, or both among adult
PLHIV with high CD4 +  cell counts, immediate ART and 6-month IPT
independently decreased the risk of death or HIV-related severe ill-
ness compared to deferred ART and no IPT.36 Despite its efficacy,
several challenges exist hampering the wide roll-out of IPT. Costs,
length of treatment and pill burden difficult its implementation and
hamper adherence. Moreover, the incidence of TB  in sub-Saharan
Africa may  increase soon after IPT discontinuation.37 As a result
of these challenges, treatment of latent TB is seldomly available
in  resource-limited settings (RLS), with only one third of  countries
currently implementing it among PLHIV.1
Shorter treatments, such as the newly recommended
weekly high dose isoniazid and rifapentine regimen for12
weeks (3HP),38 which have shown to  increase adherence
to TB preventive treatment39 may  contribute to a higher
implementation in  RLS. However, the duration of protec-
tion of 3HP is  still being evaluated in  the WHIP3TB trial
(https://clinicaltrials.gov/ct2/show/NCT02980016). Also, avail-
ability and authorization of rifapentine is not  equally distributed
throughout the world. Recently, a combination of daily rifapentine
and isoniazid (1HP) for only one month, has been evaluated in the
BRIEF trial, showing fewer adverse events and higher adherence
compared to 9-months of isoniazid.40 The implementation of  these
regimens in low endemic areas is hampered by the low availability
of rifapentine. However, there is  already some evidence of a better
completion rates and fewer adverse events when using 3HP.41
Treatment of active TB-HIV co-infection
Early initiation of anti-TB therapy and ART for patients with
HIV-associated TB is critical in  reducing morbidity and mortality
as well as reducing onwards transmission of both infections; sev-
eral important management challenges however exist: (i)  when
to start ART; (ii) significant PK drug-drug interactions (DDI); (iii)
additive toxicities of concomitant ART and anti-TB drugs; and
(iv) TB-associated immune reconstitution inflammatory syndrome
(TB-IRIS). The global HIV response serves as one of the most
inspiring undertakings in the history of global health. ART roll-
out has been impressive, with around 24 million people now on
ART globally. Several countries worldwide, including Botswana,
have met  or are  on track to  meet the UNAIDS 90:90:90 tar-
gets (90% of people living with HIV knowing their status; 90%
of those on ART; and 90% of people receiving ART virologically
suppressed by 2020).42 Conversely, TB  drug development and
roll out has moved more slowly, with no  new first-line agents
since the 1970s and pill burden and side-effects remaining a  huge
challenge. It  is  therefore perhaps not surprising that TB mortal-
ity,  particularly in HIV co-infection, has failed to decline in  line
with End-TB targets. In addition, multi-drug resistant TB  (MDR-
TB) poses a  growing challenge in  many regions.1,43 Bedaquiline
has been WHO-approved for the treatment of drug-resistant TB
for 5 years and will hopefully replace injectable agents (which can
cause deafness and kidney injury) but uptake has been slower than
anticipated.44 Clinical trials are currently underway investigating
an all oral short course (6–9-month) regimen for multi-drug (MDR)
and extensively-drug resistant (XDR) TB,  a  welcome alternative to
the existing protracted regimen including injectable agents. The
nitroimidazoles, delamanid and pretomanid, are less toxic and a
useful addition to  the armamentarium for the treatment of drug-
resistant TB. Linezolid, combined with bedaquiline and pretomanid
during six months have demonstrated a  high success rate, it is
safe and can change the paradigm of the therapy of XDR TB.45
A  number of other novel agents are in  the development pipeline
(https://www.newtbdrugs.org)  and higher dose of rifampicin and
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isoniazid are also being explored as a  way of shortening the treat-
ment duration (https://clinicaltrials.gov/ct2/show/NCT02581527).
TB-HIV drug-drug interactions
Rifamycins, the cornerstone of treatment for drug sensitive TB,
are associated with a  considerable potential for PK DDI. Rifampicin
is a potent inducer of the hepatic CYP450 enzymes (including
CYP2A6, CYP2B6, CYP2C, and CYP3A isoenzymes), P-glycoprotein
(P-gp), and uridine diphosphate glucuronosyltransferase (UGT)
1A1 enzymes.46 The magnitude of rifapentine-mediated CYP3A4
induction is predicted to be lower than rifampicin but higher
than rifabutin. This induction alters pharmacokinetics of drugs
metabolized by these pathways, reducing plasma concentrations
of several antiretroviral drugs, which risks loss of efficacy and
sequential development of resistance mutations. As a potent
enzyme inducer, rifampicin is not recommended for use in patients
receiving protease inhibitors (PI), certain non-nucleoside reverse
transcriptase inhibitors (NNRTI) such as rilpivirine, nevirapine, and
etravirine; some NRTI such as tenofovir-alafenamide; and some
integrase strand transfer inhibitors (INSTI), such as elvitegravir
and bictegravir. Rifabutin, a  weaker CYP3A4 enzyme inducer is
recommended as an alternative to rifampicin in patients receiv-
ing PI-based ART regimens. Because rifabutin is a  substrate of the
CYP450 enzyme system however, its metabolism may  be affected
by NNRTIs or PIs and rifabutin dosage adjustment is  generally rec-
ommended (Fig. 3). Efavirenz-based ART regimen is recommended
as the preferred first-line regimen globally. Recent evidence has
shown that dolutegravir, an INSTI which is currently the recom-
mended ART regimens for initial therapy by  the WHO  guidelines,
can be safely co-administered with rifampicin provided they are
dose-adjusted to  twice daily.22,47,48 The recent Reflate TB2 trial,
an open-label, phase 3, randomized clinical trial conducted in
Brazil, Côte d’Ivoire, France, Mozambique, and Vietnam comparing
another INSTI, raltegravir 400 mg BID vs. efavirenz 600 mg  QD with
TDF/3TC in PLHIV on standard TB treatment, failed to demonstrate
non-inferiority of raltegravir at week 48.49
The variety and complexity of DDI are summarized in Fig. 3.  Such
challenges are particularly stark in lower income settings where
the range of available ART is limited, rifabutin is frequently not
available, HIV viral load monitoring is not  universal, and routine
genotyping for HIV resistance profiles is  generally not available.
When to start TB treatment and ART
In patients diagnosed with active TB prior to the initiation of
ART, the decision of when to start ART is  informed by  the risk of fur-
ther immune decline, additive opportunistic infections and death
with delaying ART initiation vs. the risk of TB-IRIS, which is  greater
with earlier ART initiation.50 Several randomized controlled trials
have attempted to address the optimal timing of ART initiation.
Three large randomized controlled trials, demonstrated that early
ART in those with CD4 counts <50 cell/L  significantly reduced AIDS
events or deaths.50 In patients with CD4 cell counts <50 cells/L
therefore, ART initiation is recommended within the first 2 weeks
of TB treatment. For patients with CD4 >50 cell/L,  ART initia-
tion should be within eight weeks of starting anti-TB therapy.46
These recommendations also apply to patients with suspected or
confirmed MDR-TB.46 A randomized placebo-controlled trial con-
ducted in South Africa, Tanzania, Uganda and Zambia in 2014, and
randomizing 1675 patients with CD4 counts of 220 cells/l or more
to early ART vs ART delayed at the end of six months of TB treat-
ment, did not find differences in  TB treatment failure, TB  recurrence
or death. These results suggest that ART can be delayed until the
completion of TB  treatment among this subgroup of patients and
challenge the current WHO  recommendations.51
TB immune reconstitution inflammatory syndrome
TB-IRIS is  caused by ART-induced restoration of TB-specific
immune responses, resulting in  either the deterioration of  a  treated
infection (paradoxical IRIS) or a  new presentation of a  previ-
ously subclinical infection (unmasking IRIS). IRIS has been reported
in  8–40% following ART initiation.52 Predictors of IRIS include a
baseline CD4 count <50 cells/L; rapid on-ART restoration of  CD4
counts; high pre-ART and lower on-ART HIV viral loads; and sever-
ity of TB  disease. Most TB-IRIS occurs within 3 months of  the start
of ART, usually within the first month. Incidence of unmasking
TB-IRIS is  harder to quantify but there is concern that the recent
rapid upscaling of ‘HIV test and start,’ could result in  an increased
incidence of unmasking IRIS events to opportunistic infections.53
TB-IRIS ranges from mild to severe to life-threatening. Patients
with mild or  moderately severe IRIS can be managed symp-
tomatically. For management of severe TB-IRIS, corticosteroids are
recommended as demonstrated in a  recent RCT, although data
on the optimal dose, duration, and overall safety and efficacy are
limited.54 In the presence of IRIS,  ideally neither TB  therapy nor ART
should be stopped, as immune restoration and effective control of
the bacillary burden are both  essential to  long term survival.
TB-IRIS prevention with prednisolone prophylaxis (40 mg/day
for 2  weeks then 20 mg/day for 2 weeks started with ART) was
investigated in  a  recent clinical trial among ART-naïve adults at
high risk of TB-IRIS (within 30 days of TB treatment initiation and
CD4 count ≤100 cells/L). Grade 3 adverse events occurred more
frequently in  the placebo arm (45.4% vs. 29.4%, p =  0.01), but grade
4 adverse events were similar by arm (8.4% vs. 7.6%, p  =  0.81). The
intervention reduced the risk of TB-IRIS by 30% and further reduced
the requirement for corticosteroids to treat TB-IRIS by  53%.55
Present areas of uncertainty
Tuberculous meningitis is  the most severe form of HIV-
associated TB. TBM-associated mortality is  40–58% in PLHIV. Given
that the risks of TB-IRIS is significantly greater in CNS disease,
caution with ART initiation is  required. In  a  study conducted in
Vietnam, TBM patients were randomized to  immediate ART or to
ART deferred 2 months after initiation of TB treatment. A signifi-
cantly higher rate of severe adverse events was  seen in patients who
received immediate ART than in  those with deferred therapy (80.3%
vs. 69.1% for early and deferred ART, respectively; p  =  0.04).56 There
have been no subsequent studies to  further delineate the optimum
timing of ART in  TBM and current expert opinion is to start at 8
weeks. The use of adjuvant steroids in the treatment of extrapul-
monary TB disease, namely TBM and pericardial TB, also requires
further study in  PLHIV. In TBM, the WHO  currently recommends
initial adjuvant dexamethasone or prednisolone tapered over 6–8
weeks. However, of the nine trials which demonstrated a  mortal-
ity benefit of adjunctive steroids in  the treatment of TBM,57 only
one trial from Asia included PLHIV. In the sub-group analysis of
PLHIV, there was a non-significant reduction in  mortality and no
reduction in long term neurological disability.58 Although adjunct
steroids remain standard of care for patients with HIV-associated
TBM, a currently recruiting study in PLHIV will provide important
trial data to further inform clinical practice.59 Finally, an Indian
trial randomizing patients with TBM to  receive aspirin or placebo
as adjuvant to antitubercular treatment showed an absolute risk
reduction of stroke in 19% and a 21.7% reduction in  three-month
mortality.60
There is considerable hope that scale up of HIV “test and
start” and IPT uptake will reduce TB/HIV incidence and mortality.
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However, ongoing evolution of MTB  and HIV drug resistance is a
competing challenge for which potent, tolerable, affordable and
available drugs are the only answer. Moreover, IRIS is  likely to  pose
an ongoing clinical challenge for which other safe host-directed
therapies are required.
Challenges of TB/HIV co-infection in resource-limited
settings
The deadly TB/HIV association remains a  major public health
concern in RLS. Still today, TB  is  the main cause of morbidity and
mortality amongst PLHIV. In turn, HIV represents the main TB
epidemic driver in  certain regions. TB develops more frequently,
recurs more likely and often remains undiagnosed and untreated
in PLHIV.1,61 This threat is  exacerbated by the growing prevalence
of DR-TB. Since 2004, the WHO recommends a’collaborative HIV/TB
activities’ package consisting in  integrating service delivery, reduc-
ing TB burden through early ART initiation and reducing HIV burden
in patients with presumptive and diagnosed TB62 (Table 1). In RLS,
the clinical challenges managing HIV/TB co-infection are aggra-
vated by programmatic issues related to outdated policies and
practices. Improved diagnostics, cheaper, more effective anti-TB
regimens and improved ART  coverage are some of the main chal-
lenges ahead alongside limitations in  human, financial resources
and health infrastructure.63
In  2017 in  the highest TB/HIV burden countries, 66% of  patients
with TB were aware of their HIV status.1 However, merely 46% of
estimated incident TB  cases amongst PLHIV were reported, leav-
ing an enormous gap of PLHIV with non-identified TB,  despite
systematic TB  screening for  PLHIV is  broadly recommended. Diag-
nostic gaps remain a  big challenge, the cost-effectiveness of Xpert
MTB/RIF is controversial, and only half of the countries recom-
mending initial Xpert MTB/RIF testing in  PLHIV are  implementing
Fig. 3. Summary of drug-drug interactions between commonly used antiretroviral and antituberculous agents.
The  website www.hiv-druginteractions.org should be used for up-to-date and more detailed interaction details.
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Fig. 3. (Continued)
Table 1
EndTB strategy pillars and components.
Pillars Components
Integrated, patient-centered care and
prevention
Early diagnosis of tuberculosis including universal drug-susceptibility testing,and systematic
screening of contacts and high-risk groups
Treatment of all people with tuberculosis including drug-resistant tuberculosis, and patient
support
Collaborative tuberculosis/HIV activities, and management of co-morbidities
Preventive treatment of persons at high risk, and vaccination against tuberculosis
Bold  policies and supportive systems Political commitment with adequate resources for tuberculosis care and prevention
Engagement of communities, civil society organizations, and public and private care providers
Universal health coverage policy, and regulatory frameworks for case notification, vital
registration, quality and rational use of medicines, and infection control
Social  protection, poverty alleviation and actions on other determinants of tuberculosis
Intensified research and innovation Discovery, development and rapid uptake of new tools, interventions and strategies
Research to optimize implementation and impact, and promote innovations
Adapted from WHO  http://www.who.int/tb/post2015 TBstrategy.pdf.
it.64–66 With advanced HIV disease rates globally plateauing and
being TB a leading cause of death in these patients, the effec-
tive implementation of newer tools like TB-LAM, proven to reduce
mortality, are essential.64,66 However, despite the WHO  rec-
ommendation, TB-LAM implementation is rare, not included in
guidelines and often confined to research use.67 Also, TB  diag-
nostics in children, access to child-friendly drug formulations,
drug-sensitivity testing and access to  second line anti-TB drugs
pose additional challenges.39,68,69
In addition, despite knowing that  ART reduces TB risk, ART cov-
erage among TB-patients remains suboptimal in RLS. The wide and
safe implementation of the “Test and Start” strategy together with
the roll-out of new ARVs such as Dolutegravir could further impact
TB  incidence.
Moreover, as mentioned, only a  third of countries with TB pre-
vention recommendations are implementing latent TB treatment
among PLHIV. Despite shorter effective strategies are available
uptake is still limited.70–73
ART and TB  service decentralization, task-shifting and one-
stop integrated services increases uptake, improves outcomes and
lowers patient costs.74–80 Nevertheless, in many settings and in
particular in  West and Central Africa, with very low ART coverage
and centralized and vertical TB and HIV programs, dedicated efforts
to HIV/TB integration should be  considered.81 Finally, TB screen-
ing as part of services like ante-natal care remains challenging.82
Additional barriers relate to funding, being HIV/TB integration the
TB programmatic component with lower funding allocation. This
leaves countries relying on partnerships with other departments or
organizations.1 Furthermore, monitoring and evaluation systems
are often not  in  place; improvements on indicators measuring ART
impact and TB prevention are required. Collaborative TB/HIV activ-
ities are a  pillar of the EndTB strategy yet,  outcome data in  RLS is
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lacking83 (Table 1). Finally, social barriers related to health seeking
behavior, stigma or lack of community mobilization are not always
addressed. Research agendas in RLS should aim to  urgently answer
these remaining gaps.
Conclusions
More than twenty years after the advent of ART, and despite
wide effective roll-out in resource-limited settings during the past
two decades, TB-HIV co-infection remains as a  significant global
health challenge. TB-HIV co-infection affects millions of people
worldwide and threatens global public health. Several barriers exist
for the delivery of optimal patient centered TB and HIV prevention
and care. Joint action between TB and HIV programs is  needed to
overcome these barriers and reduce the global burden of this deadly
interaction. Fighting TB/HIV co-infection requires strong political
commitment to adopt a  comprehensive service integration. While
countries are making progress, much work remains to be done to
ensure policy adoption and implementation across all communities
globally.
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